Loading
Latest filing published 13 Jun 2022 for Lyra Therapeutics, Inc., €19k.
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
C. Ann Merrifield (board member) discloses dealings in 5 companies, chiefly Juniper Pharmaceuticals Inc, Flexion Therapeutics Inc and Playtex Products Inc. We count 25 filings; the first trade dates from 25 April 2006 and the latest from 10 June 2022.
Every open-market trade on record is a purchase: 13 purchases worth €262k, and no sale. The totals do not cover 1 filing with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 6 share grants and 1 option exercise. In 2022 alone, the filings show 3 purchases and no sales.
A typical purchase (the median) is worth €18k. 3 out of 6 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.
On 13 June 2022 came the latest disclosure, an open-market purchase for €19k in Lyra Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations